Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support

• Telomir-1 has now entered GMP preparation, and Ketamir-2 has completed the Phase 1 SAD stage, reflecting steady advancement of both programmes
• These milestones mark tangible progress in development and demonstrate the effectiveness of the ongoing collaboration
• Recipharm provides end-to-end support, including API synthesis, process development and GMP manufacturing, enabling seamless transition from research into clinical development.

 Recipharm, a leading global contract development and manufacturing organisation (CDMO), today highlighted the progress of Telomir and MIRA Pharmaceuticals, with Telomir-1 advancing toward first-in-human studies and Ketamir-2 continuing through its clinical development pathway.

Telomir has initiated GMP preparation activities for its lead compound, Telomir-1, an orally administered small molecule being evaluated for its role in regulating metal ion balance and epigenetic DNA methylation patterns linked to cellular aging and age-related biological stress. Recipharm has supported Telomir with API synthesis, process development, and early GMP manufacturing activities, enabling the transition from research toward clinical evaluation.

In parallel, MIRA has completed the Phase 1 SAD (Single Ascending Dose) stage of clinical development for Ketamir-2, a next-generation, non-scheduled ketamine analogue being evaluated for neuropathic pain. Recipharm provided GMP manufacturing support for the program to enable clinical supply. As reported by MIRA, Ketamir-2 was generally well-tolerated in the Phase 1 SAD study and did not exhibit the ketamine-like effects typically associated with dissociation or psychoactivity. These findings support continued clinical development.

Greg Behar, CEO of Recipharm, said: “The progress made by Telomir and MIRA reflects the strength of their science, vision, and commitment to addressing important medical needs. At Recipharm, we are proud to have built a true partnership with Erez Aminov and his teams, providing the expertise and consistent quality that help advance these innovative programs. Partnerships like these are at the heart of our mission to enable breakthroughs that can make a real difference for patients.”

Erez Aminov, CEO of Telomir Pharmaceuticals and MIRA Pharmaceuticals, said: “The work underway with Telomir-1 and Ketamir-2 is deeply important, reflecting our commitment to advancing new scientific approaches in areas where current options are limited. Recipharm’s technical rigor and dependability have been essential in progressing both programs. We are proud of the partnership and look forward to continuing this important work together.”

Ends)

For more information

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company focused on the epigenetic roots of cancer, aging, and age-related disease. The Company’s lead program, Telomir-1, is an orally administered small molecule being evaluated for its potential to influence metal ion balance and epigenetic DNA methylation pathways associated with cellular aging and biological stress. Telomir is advancing Telomir-1 toward first-in-human evaluation.

For more information, please visit www.telomirpharma.com.

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company focused on developing novel oral therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company’s pipeline includes innovative drug candidates being evaluated in areas of significant unmet need, including neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline.

For more information, please visit www.mirapharmaceuticals.com.

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) employing over 5,000 employees worldwide. Recipharm provides manufacturing services of pharmaceuticals in various dosage forms, including sterile fill & finish, oral solid dosage and biologics; clinical trial material development and manufacturing services; and pharmaceutical product development. Its Recipharm Advanced Bio segment works with customers to develop and commercialise advanced therapy medicinal products (ATMPs): pre-clinical to clinical development, commercial development and manufacture for new biological modalities, encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production.

Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. It operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden and the US.

For more information on Recipharm, please visit www.recipharm.com and www.recipharm-ab.com

Media contact:

Guenaelle Holloway, Head of communications
[email protected]
+44 7730 303 708